Linked Life Data

15589070

Source:http://linkedlifedata.com/resource/pubmed/id/15589070

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2004-12-13
pubmed:abstractText
Clinical islet transplantation has recently received a strong impulse from the results obtained with the introduction of the Edomonton group. However, islet transplantation is at present a minimally invasive procedure and offers for the future the unique possibility of being performed under donor-specific tolerant conditions because islets may potentially be engineered in vitro. In addition, various approaches such as in vitro islet expansion, or xenogenic islets could make the availability of donor tissues unlimited. Recent advances in tissue engineering (technology) and cell biology may allow for the development of novel strategies for the treatment and cure of type I diabetes. In particular, it is now possible to envisage restoration of insulin secretion by cell-replacement therapy. And it will be necessary to ensure that implanted beta-cells are protected in some way from recognition by the immune system (a bio-artificial endocrine pancreas).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0753-3322
pubmed:author
pubmed:issnType
Print
pubmed:volume
58
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
605-9
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Diabetes mellitus: rational basis, clinical approach and future therapy.
pubmed:affiliation
Division of Cell Replacement and Regenerative Medicine, Medical Research Institute, Tokyo Women's Medical University, Tokyo 162-8666, Japan.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't